Effects of the angiotensin‐converting enzyme inhibitor alacepril on exercise capacity and neurohormonal factors in patients with mild‐to‐moderate heart failure
Authors:
- 17 October 2002
- journal article
- research article
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 29 (12) , 1060-1065
Abstract
Summary: 1. Alacepril is a long‐acting, sulphydryl‐containing angiotensin‐converting enzyme inhibitor. Data are limited regarding the effects of alacepril on exercise tolerance in patients with chronic heart failure (CHF). The aim of the present study was to determine the effects of chronic alacepril treatment on exercise capacity and neurohormones in patients with CHF.2. The effects of 12 weeks treatment with alacepril on clinical, echocardiographic and cardiopulmonary exercise variables were studied in 18 CHF patients (mean age: 63 ± 2 years; New York Heart Association (NYHA) class I n = 6, class II n = 10, class III n = 2) in a cross‐over fashion. Resting levels of plasma noradrenaline, renin–angiotensin system activity and natriuretic peptides were evaluated.3. Treatment with alacepril significantly improved NYHA functional class and decreased cardiothoracic ratio (60.1 ± 2.0 vs 58.1 ± 1.9% for baseline vs alacepril, respectively; P < 0.01). Cardiac dimensions by echocardiogram were decreased after alacepril therapy. Peak Vo2 (17.7 ± 1.2 vs 19.5 ± 1.3 mL/min per kg; P < 0.01) and anaerobic threshold (11.7 ± 0.6 vs 13.2 ± 0.9 mL/min per kg; P < 0.01) increased with alacepril treatment. Plasma noradrenaline and plasma angiotensin II levels were not altered, but plasma aldosterone (77.7 ± 13.5 vs 51.7 ± 9.7 pg/mL; P < 0.01), atrial natriuretic peptide (ANP; 86.5 ± 20.3 vs 43.6 ± 7.6 pg/mL; P < 0.05) and brain natriuretic peptide (BNP; 222.7 ± 59.3 vs 117.7 ± 34.3 pg/mL; P < 0.05) levels decreased after alacepril treatment.4. These results suggest that treatment with alacepril improves functional status and exercise capacity in patients with mild‐to‐moderate CHF. Neurohormones were favourably influenced by alacepril therapy, with significant decreases in plasma aldosterone, ANP and BNP levels.Keywords
This publication has 28 references indexed in Scilit:
- Effects of Enalapril on the Exercise Capacity and Neurohumoral Factors during Exercise in Patients with Chronic Heart FailureCardiology, 1997
- Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure.Heart, 1994
- Effects of lisinopril on cardiorespiratory, neuroendocrine, and renal function in patients with asymptomatic left ventricular dysfunction.Heart, 1993
- Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease.Heart, 1993
- Effect of long-term enalapril therapy on cardiopulmonary exercise performance in men with mild heart failure and previous myocardial infarctionJACC, 1991
- Plasma atrial natriuretic polypeptide as an index of left ventricular end-diastolic pressure in patients with chronic left-sided heart failureAmerican Heart Journal, 1989
- An analysis of the determinants of exercise performance in congestive heart failureAmerican Heart Journal, 1987
- Effectiveness of converting enzyme inhibition (enalapril) for mild congestive heart failureThe American Journal of Cardiology, 1986
- Captopril in heart failure. A double blind controlled trial.Heart, 1984
- A placebo-controlled trial of captopril in refractory chronic congestive heart failureJACC, 1983